Product · #26 of 27 · black cohosh blend
Gaia Herbs Menopause Support Daytime
Capsule (liquid phyto-cap) from Gaia Herbs, made by Gaia Herbs. Daily serving: 3 capsules (1 capsule 3× daily between meals).
Last updated · Price and ratings checked Nov 19, 2026
In short: Gaia Herbs Menopause Support Daytime scores 40.2/100 in our ranking (#26 of 27). It costs $1.53 a day at the regular price. Evidence: black cohosh herb (not iCR extract); best ingredient grade C+ (Red clover). No NSF registry listing was confirmed.
Pros
- None stood out.
Cons
- No NSF registry listing confirmed.
- Expensive: $1.53 a day at the label dose.
- Evidence: black cohosh herb (not iCR extract).
- Proprietary blend: some ingredient amounts are not disclosed.
- Contains black cohosh: rare liver-injury reports, and adulteration is common across the category.
- Contains St John's wort, which interacts with many medicines.
Flags
Drug interactionsLiver caution
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| Organic black cohosh root extract200 mg/capsule × 3 | 600 mg | Black cohosh C |
| Herbal extract blend: alfalfa, red clover, milky oat seed, chaste tree, dandelion root & leaf, St. John's wort, vervain, sage (total)430 mg/capsule × 3; individual amounts not disclosed | 1,290 mg | Red clover C+ Sage C Vitex (chasteberry) C- St John's wort + black cohosh C+ |
Evidence
Our evidence score: 18/40, because: black cohosh herb (not iCR extract).
Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.
Ingredient evidence
- Black cohosh C (600 mg here)
Black cohosh is the most-studied herb for occasional hot flashes and night sweats associated with menopause*. Independent trials and a Cochrane review found no clear benefit over placebo, other reviews found a small one, and rare liver-injury reports exist. The Menopause Society 2023: Not recommended (Level I) – 'insufficient evidence to support use for VMS'. - Red clover C+ (1,290 mg here)
Red clover isoflavones have been studied for occasional hot flashes*. Some meta-analyses report short-term effects, but a 12-month NIH-funded trial and a Cochrane review found no clear benefit over placebo. The Menopause Society 2023: Not specifically named (supplements not recommended). - Sage C (1,290 mg here)
Sage has traditionally been used for occasional sweating and hot flashes*. A 2023 meta-analysis of four trials found no significant effect on how often hot flashes happen. The Menopause Society 2023: Not assessed. - Vitex (chasteberry) C- (1,290 mg here)
Vitex (chasteberry) has better evidence for menstrual-cycle comfort than for menopause. The largest menopause trial (100 women, combined with St John's wort) found no benefit over placebo. The Menopause Society 2023: Not recommended (Level II). - St John's wort + black cohosh C+ (1,290 mg here)
A fixed combination of black cohosh and St John's wort has been studied for occasional mood changes associated with menopause*. St John's wort interacts with many common medicines. The Menopause Society 2023: Black cohosh not recommended; combination noted as possibly augmented.
Studies
Studies on its ingredients (24)
-
Black cohosh (Cimicifuga spp.) for menopausal symptoms.
An independent Cochrane review pooled 16 trials with about 2,000 women taking black cohosh (usually 40 mg a day for around 5 months). Women taking black cohosh did not have fewer hot flashes than women on a dummy pill, and the reviewers called the safety data inconclusive.
- Who
- 16 RCTs, 2,027 women
- Dose
- median 40 mg/day black cohosh extract
- Duration
- mean 23 weeks
- Result
- No difference vs placebo in hot-flush frequency (MD +0.07/day; 95% CI -0.43 to 0.56; 3 trials, 393 women) or symptom scores; hormone therapy beat black cohosh.
- Funding
- Cochrane review (independent). Independent / academic
-
Black cohosh extracts in women with menopausal symptoms: an updated pairwise meta-analysis.
A 2023 analysis of 22 studies (about 2,300 women) found black cohosh extracts did somewhat better than placebo for overall menopause symptoms and hot flashes, with a small-to-moderate effect. It did not help anxiety or low mood, and the studies varied a lot in product and quality.
- Who
- 22 articles, 2,310 women
- Dose
- various black cohosh extracts
- Duration
- various
- Result
- Pooled improvement vs placebo in overall menopausal symptoms (Hedges g 0.58) and hot flashes (g 0.32); no significant effect on anxiety or depression.
- Funding
- Academic; one author reported speaker fees from supplement/pharma companies incl. Cimic. Some author ties
-
Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence.
This review looked only at the specific black cohosh extract in Remifemin and found it beat placebo for menopause symptoms, especially at higher doses or combined with St John's wort. Several authors work for the company that makes Remifemin, so read it as a manufacturer-backed summary.
- Who
- 35 studies + 1 MA, 43,759 women (13,096 on iCR)
- Dose
- isopropanolic extract (iCR, Remifemin), 20–>40 mg/day
- Duration
- various
- Result
- SMD -0.69 vs placebo for neurovegetative/psychological symptoms; larger effect at higher dose and with St John's wort; no hepatotoxicity signal in trial data.
- Funding
- Co-authored by staff of Schaper & Brümmer (maker of Remifemin) – manufacturer-affiliated. Industry-linked
-
Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.
About 300 women with menopause symptoms took Remifemin-type black cohosh (40 mg a day) or a dummy pill for 12 weeks. Symptom scores improved more with black cohosh, mostly in women early in menopause, and side effects were similar to placebo.
- Who
- 304 women
- Dose
- iCR (Remifemin) equivalent to 40 mg root/day
- Duration
- 12 weeks
- Result
- More effective than placebo on the Menopause Rating Scale (P<.001), mainly in early menopause; hot-flush subscore was the most responsive.
- Funding
- Funding not stated in the abstract (study of the manufacturer's extract). Funding not stated
-
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.
In a publicly funded US trial, 132 women took black cohosh (20 mg twice a day) or placebo for 4 weeks each. Hot flashes dropped slightly more on placebo than on black cohosh, so the trial found no benefit.
- Who
- 132 women (history of or concern about breast cancer; crossover)
- Dose
- black cohosh 20 mg twice daily
- Duration
- two 4-week periods (crossover)
- Result
- Hot-flash frequency fell 17% on black cohosh vs 26% on placebo (P=.36) – no benefit.
- Funding
- NCCTG/NCI cooperative group (public funding). Independent / academic
-
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.
The US government-funded HALT study followed 351 women for a year. Black cohosh (160 mg a day), a 10-herb blend, and the blend plus more soy food did no better than a dummy pill for hot flashes, while hormone therapy clearly worked.
- Who
- 351 women aged 45–55
- Dose
- black cohosh 160 mg/day; multibotanical; multibotanical + soy diet; hormone therapy; placebo
- Duration
- 12 months
- Result
- No herbal arm differed from placebo at 3, 6 or 12 months (<1 hot flash/day difference); hormone therapy reduced ~4 symptoms/day vs placebo.
- Funding
- US NIH (NCCAM/NIA) – HALT study, independent. Independent / academic
-
Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.
In a year-long, government-funded trial, women took black cohosh, red clover, hormone therapy or a dummy pill. Only hormones beat placebo for hot flashes; both herbs looked safe but did not reduce hot flashes more than placebo.
- Who
- 89 women (4 arms)
- Dose
- standardized black cohosh and red clover extracts vs CEE/MPA vs placebo
- Duration
- 12 months
- Result
- Hot-flash reduction: black cohosh 34%, red clover 57%, placebo 63%, hormones 94%; neither botanical beat placebo. Both appeared safe over 12 months.
- Funding
- NIH (NCCAM/ODS) botanical center, University of Illinois – independent. Independent / academic
-
Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.
122 women took a different (ethanol-based) black cohosh extract or placebo for 12 weeks. Overall it did not beat placebo; only women with more severe symptoms seemed to benefit, which is a weaker, after-the-fact finding.
- Who
- 122 women with ≥3 hot flashes/day
- Dose
- dried ethanolic black cohosh extract (non-Remifemin)
- Duration
- 12 weeks
- Result
- No superiority over placebo overall; benefit only in subgroup with moderate–severe symptoms (Kupperman ≥20: -47% vs -21%).
- Funding
- Not stated in abstract. Funding not stated
-
Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract.
This analysis of 5 trials found no change in liver blood tests in women taking the Remifemin extract for up to 6 months. It was written by the manufacturer and covers only short-term use.
- Who
- 5 RCTs, 1,117 women
- Dose
- iCR 40–128 mg/day
- Duration
- 3–6 months
- Result
- No effect on liver enzymes (AST/ALT) vs reference groups.
- Funding
- Written by Schaper & Brümmer (Remifemin maker) staff. Industry-linked
-
United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.
The US Pharmacopeia reviewed 30 reports of liver injury in people using black cohosh. It could not prove black cohosh caused them but recommended a label warning to stop and see a doctor if liver symptoms appear.
- Who
- 30 case reports of liver damage
- Dose
- various products
- Duration
- n/a
- Result
- All 30 liver cases rated 'possible' (none probable/certain); USP recommended a cautionary liver label.
- Funding
- US Pharmacopeia expert committee (independent standard-setter). Independent / academic
-
Black cohosh and breast cancer: a systematic review.
A systematic review of black cohosh and breast cancer found no sign it increases breast-cancer risk, but also no proof it reduces hot flashes in women who have had breast cancer.
- Who
- 26 studies (14 RCTs)
- Dose
- various
- Duration
- various
- Result
- No evidence black cohosh raises breast-cancer risk; no proven hot-flash benefit in breast-cancer patients vs placebo.
- Funding
- Academic (Canadian naturopathic/academic group). Independent / academic
-
Actaea racemosa L. Is More Effective in Combination with Rhodiola rosea L. for Relief of Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study.
220 women in Georgia took black cohosh alone, black cohosh plus Rhodiola, or placebo for 12 weeks; the combination worked best. An author is paid by the company that sells the combination.
- Who
- 220 women
- Dose
- black cohosh 6.5 mg; black cohosh 500 mg; Rhodiola+black cohosh (Menopause Relief EP); placebo
- Duration
- 12 weeks
- Result
- Rhodiola+black cohosh beat black cohosh alone and placebo on all symptom scales.
- Funding
- Author has contract with Europharma USA (seller) and heads Phytomed AB. Industry-linked
-
Complementary therapies for management of menopausal symptoms: a systematic review to inform the update of the International Menopause Society recommendations on women's midlife health.
A 2026 International Menopause Society evidence review rated black cohosh's benefit for hot flashes as moderate-certainty and most other supplements as low-certainty.
- Who
- 158 studies
- Dose
- various
- Duration
- n/a
- Result
- Moderate-certainty evidence supports black cohosh for vasomotor/menopausal symptoms and vitamin D for fracture risk; most complementary therapies low/very-low certainty.
- Funding
- International Menopause Society review. Independent / academic
-
Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone.
244 Chinese women took Remifemin-type black cohosh or the hormone-like drug tibolone for 12 weeks. Symptom scores fell similarly in both groups, but there was no placebo group, so the size of the true effect is unclear.
- Who
- 244 Chinese women
- Dose
- iCR (Remifemin) equivalent to 40 mg/day vs tibolone 2.5 mg/day (no placebo)
- Duration
- 12 weeks
- Result
- Kupperman Index fell similarly with iCR and tibolone; iCR better tolerated.
- Funding
- Not stated in abstract. Funding not stated
-
Phytoestrogens for menopausal vasomotor symptoms.
An independent Cochrane review of 43 trials found no conclusive proof that phytoestrogens (soy, red clover) reduce hot flashes. High-genistein soy extracts looked more promising, and placebo effects were large.
- Who
- 43 RCTs, 4,364 women
- Dose
- various phytoestrogens
- Duration
- various
- Result
- No conclusive evidence of reduced hot flushes; Promensil (red clover) not better than placebo (MD -0.93/day, NS); genistein >30 mg/day may help; strong placebo effect.
- Funding
- Cochrane review (independent). Independent / academic
-
Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.
A JAMA analysis of 62 studies found plant estrogens such as soy cut about one hot flash a day compared with placebo – a modest effect – and most studies were of low quality.
- Who
- 62 studies, 6,653 women
- Dose
- phytoestrogens and other plant therapies
- Duration
- various
- Result
- Phytoestrogens: -1.31 hot flashes/day; soy isoflavones -0.79/day; 74% of RCTs at high risk of bias.
- Funding
- Academic (Erasmus MC); industry co-funding reported in paper is not verified here. Industry-linked
-
Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Pooling 8 trials, red clover reduced hot flashes by about 1–2 a day more than placebo, mostly in women with frequent hot flashes taking higher doses.
- Who
- 8 trials (10 comparisons)
- Dose
- red clover isoflavones
- Duration
- ~12 weeks
- Result
- -1.73 hot flushes/day vs placebo (95% CI -3.28 to -0.18), mainly in women with ≥5/day and ≥80 mg isoflavones.
- Funding
- Authors declared no conflicts. Independent / academic
-
Red clover extract for alleviating hot flushes in postmenopausal women: a meta-analysis.
A review found red clover modestly reduced hot flashes over 3–4 months, but the benefit was no longer seen at 12 months.
- Who
- meta-analysis
- Dose
- red clover extract
- Duration
- 3–4 months and 12 months
- Result
- Effective at 3–4 months (MD -1.34/day) but not at 12 months.
- Funding
- Academic (Monash). Independent / academic
-
Effectiveness of Menosan® Salvia officinalis in the treatment of a wide spectrum of menopausal complaints. A double-blind, randomized, placebo-controlled, clinical trial.
80 Swiss women took a fresh sage extract or placebo for 4 weeks. Menopause scores and hot flashes improved more with sage. The manufacturer sponsored the study, and 4 weeks is short.
- Who
- 80 women aged 48–65
- Dose
- Menosan sage (3,400 mg fresh-leaf ethanolic extract)
- Duration
- 4 weeks
- Result
- MRS -39% (P=.002 vs placebo); hot-flush severity -55% from week 3.
- Funding
- Sponsored by A. Vogel (manufacturer); author employee. Industry-linked
-
First time proof of sage's tolerability and efficacy in menopausal women with hot flushes.
In a study without a placebo group, women taking fresh sage had 64% less hot-flash intensity after 8 weeks. Without placebo comparison this cannot separate sage from placebo effect.
- Who
- 71 women (single arm, no placebo)
- Dose
- fresh sage leaf tablet once daily
- Duration
- 8 weeks
- Result
- Hot-flush intensity score -50% at 4 weeks, -64% at 8 weeks vs baseline.
- Funding
- Not stated in abstract (manufacturer product). Funding not stated
-
The Effect of Salvia Officinalis on Hot Flashes in Postmenopausal Women: A Systematic Review and Meta-Analysis.
A small review of 4 sage studies did not find a statistically clear reduction in hot flashes overall.
- Who
- 4 studies, 310 women
- Dose
- Salvia officinalis
- Duration
- various
- Result
- Hot-flash frequency effect not significant (ES -1.12, CI -2.37 to 0.14); severity NS.
- Funding
- Academic (Iran). Independent / academic
-
Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial.
100 Australian women took a St John's wort + chasteberry combination or placebo for 16 weeks. It did not beat placebo – the largest, most rigorous vitex trial.
- Who
- 100 women
- Dose
- St John's wort + Vitex combination
- Duration
- 16 weeks
- Result
- No difference vs placebo for hot flushes, Greene scale or depression.
- Funding
- Academic (Australia). Independent / academic
-
Comparison of Vitex agnus-castus Extracts with Placebo in Reducing Menopausal Symptoms: A Randomized Double-Blind Study.
52 Iranian women took chasteberry or placebo for 8 weeks; symptom questionnaires improved more with vitex. Small and questionnaire-based.
- Who
- 52 women (Iran)
- Dose
- Vitex agnus-castus extract
- Duration
- 8 weeks
- Result
- Total menopausal, anxiety and vasomotor scores lower vs placebo.
- Funding
- No conflicts reported. Independent / academic
-
Black cohosh and St. John's wort for climacteric complaints: a randomized trial.
301 women with menopause symptoms and low mood took a black cohosh + St John's wort combination or placebo for 16 weeks. Symptoms and mood improved much more on the combination. St John's wort interacts with many medicines, including birth control and blood thinners.
- Who
- 301 women with psychological symptoms
- Dose
- iCR black cohosh + St John's wort fixed combination
- Duration
- 16 weeks
- Result
- Menopause Rating Scale fell 50% vs 19.6% with placebo; depression score fell 41.8% vs 12.7% (both P<.001).
- Funding
- Not stated in abstract (manufacturer product, Remifemin plus). Funding not stated
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $30.59 (60 units, 20 days at label dose) |
|---|---|
| Cost per day | $1.53 |
| Subscription | None listed |
| Price notes | 60 caps = 20 days at label dose. Nighttime version $30.59. Amazon listings currently unavailable. |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: No Amazon rating
Brand site: ★ 4.7, 266 reviews on gaiaherbs.com (checked Nov 19, 2026). Brand-site reviews are moderated by the brand.
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- Certified B Corporation (company) Registry-verified
Claims made by the brand
- “purity-tested (microbes, heavy metals) in on-site ISO lab” Brand claim
- “vegan” Brand claim
- “soy/gluten/dairy-free” Brand claim
- “USDA Organic ingredients” Brand claim
- “Non-GMO Project logo on About page” Brand claim
Registry check: NSF/ANSI 173: not found
Who's behind it
| Brand | Gaia Herbs |
|---|---|
| Owner / company | Gaia Herbs, Inc. (Brevard, NC). |
| Founders | Ric Scalzo (1987). |
| Where it's made | Brevard, North Carolina (own farm, ISO lab, manufacturing). |
| Medical advisors named | None named on the pages we read. |
| Source | gaiaherbs.com |
Flags & safety
Legal, regulatory and quality flags
- Contains St. John's wort – major drug interactions (incl. hormonal contraceptives, SSRIs, anticoagulants).
- Black cohosh liver caution.
- Systematic review (Natural Product Reports 2024): 42.2% of 322 black cohosh samples across 78 publications adulterated/mislabeled, mainly with Asian Actaea species. pubs.rsc.org
- DNA barcoding (J AOAC 2012): 9 of 36 (25%) US black cohosh supplements matched Asian Actaea. pubmed.ncbi.nlm.nih.gov
Ingredient safety notes
- Black cohosh: Rare liver injury reports (USP: 30 cases 'possible' causality; ODS: ≥83 cases worldwide, causality unproven). USP-recommended label: discontinue if liver disorder or symptoms of liver trouble. No evidence of increased breast-cancer risk (Fritz 2014), but safety after breast cancer not established (NCCIH). Possible interaction with statins (NCCIH).
- Red clover: Phytoestrogen – same caution as isoflavones in hormone-sensitive conditions; 12-month safety acceptable in Geller 2009.
- Sage: Sage contains thujone; avoid high-dose essential oil (general caution, not verified here). Unverified
- Vitex (chasteberry): Few AEs; avoid with dopaminergic drugs/hormonal contraception (general caution).
- St John's wort + black cohosh: St John's wort induces CYP3A4/P-gp: reduces effect of oral contraceptives, anticoagulants, antidepressants, tamoxifen-relevant concerns – major interaction risk (general pharmacology; not verified here). Photosensitivity. Unverified
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.